This pivotal study will determine the bioequivalence of generic fenofibrate [LCP-Feno], which includes MeltDose technology, with branded formulations of fenofibrate.
Latest Information Update: 24 Mar 2010
At a glance
- Drugs Fenofibrate (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics; Registrational
- Sponsors Veloxis Pharmaceuticals
- 24 Feb 2010 LifeCycle Pharma predicts that this study will be initiated later in 2010.
- 18 Jun 2008 New trial record.